Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large, phase III trials

European Journal of Cancer

Volumn 38, Issue SUPPL. 2, 2002, Pages

  Twelves, C ^a  

^a CRC Department of Medical Oncology   (United Kingdom)

Author keywords

Capecitabine; Clinical trial; Colorectal cancer; Efficacy; Fluoropyrimidines; Safety

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0036176033     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)80012-0     Document Type: Article

References (16)

1. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
2. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
3. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumours
4. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
5. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
6. Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: Results of a large phase III study
7. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
8. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
9. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients
10. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
11. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line chemotherapy for advanced/metastatic breast cancer
12. Future treatment options with capecitabine in solid tumours
13. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
14. 24h) with or without folinic acid (FA) vs. bolus 5-Fu/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomised phase III study of the EORTC GITCCG and the AIO
15. Patient preferences for oral versus intravenous palliative chemotherapy
16. A randomised crossover trial comparing oral UFT (uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU) +LV for patient preference and pharmacokinetics in advanced colorectal cancer